

22 June 2020
EFPIA Japan

EFPIA Japan publishes its initiatives in response to COVID-19

TOKYO—22 June 2020— EFPIA Japan announced today that it published its member companies' initiatives in the research and development of vaccines and therapeutics for COVID-19 on its website. EFPIA Japan members are joining forces with the global community to tackle the pandemic by ensuring pharmaceutical supply, searching for vaccines and therapeutics and supporting governments and community through research collaboration and financial and in-kind donations. As the impact of COVID-19 continues to be felt across the world, EFPIA Japan remains committed to global efforts to care for those affected.

At least seven EFPIA Japan member companies are engaged in or collaborate for the development of COVID-19 vaccines and more than 13 companies for the development of therapeutics for COVID-19 either with new compounds or their marketed products with potential efficacy in treating COVID-19. EFPIA Japan members are working collaboratively across the research and healthcare communities, including the Innovative Medicines Initiative of the European Union and the COVID-19 Therapeutics Accelerator initiated by the Bill & Melinda Gates Foundation and others. Further details are available on the EFPIA Japan website (<http://efpia.jp/english-covid-19/index.html>).

To live its commitment to bringing new medicines to improve health and quality of life, EFPIA Japan strives for early introduction of COVID-19 vaccines and therapeutics and to facilitate access to them.

About EFPIA Japan (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 22 R&D-based European pharmaceutical companies operating in Japan. In 2019, combined sales from the member companies accounted for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-



makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations)

(<http://www.efpia.eu>)

EFPIA, EFPIA Japan's partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

Contact:

Yuko Kidoguchi, EFPIA Japan Messaging & Communications Committee

1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268

Bayer Holding Ltd.

Tel: 03-6266-7757

Email: yuko.kidoguchi@bayer.com